相关实验视频
Updated: Jan 10, 2026

05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
1.5K
肥胖在慢性病进展中的作用
Austin Dada1, Jing Ren2,3, Yao Shi2,3
1M3, University of Missouri School of Medicine, Columbia, MO, 65211, USA.
Current research in physiology
|November 24, 2025
概括
肥胖通过不同的机制显著导致慢性病 (CKD). 认识到与肥胖相关的病 (ORKD) 对于开发有针对性的干预措施来减缓CKD进展至关重要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是一个全球流行病,与2型糖尿病 (T2DM) 和慢性病 (CKD) 等慢性疾病有关.
- 慢性病越来越多地被认为是肥胖的结果,可能会发展为末期病 (ESRD).
- 与糖尿病病相比,与肥胖相关的病 (ORKD) 呈现出明显的病理生理病变.
研究的目的:
- 检查将肥胖与CKD发展和进展联系在一起的病理生理机制.
- 为了区分ORKD和糖尿病病.
- 强调肥胖是慢性脏病的可修改风险因素,并探索有针对性的干预措施.
主要方法:
- 审查当前的临床前和临床证据.
- 综合连接肥胖和脏疾病的病理生理路径.
- 对CKD针对肥胖的针对性干预措施的分析.
主要成果:
- 肥胖会通过与糖尿病不同的特定机制驱动CKD,其特点是自由脂肪酸和甘油三沉积.
- ORKD涉及独特的病变,与糖尿病病不同.
- 肥胖是CKD发病率和进展的一个显著的,可修改的风险因素.
结论:
- 糖尿病病是一种独特的临床实体,需要与糖尿病病分开的特定管理策略.
- 准肥胖和过可能会降低CKD发病率并延迟ESRD.
- 了解肥胖在CKD中的作用对于公共卫生和临床实践至关重要.
相关概念视频
Chronic Kidney Disease I: Introduction
549
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
549
Chronic Kidney Disease III: Interprofessional Care
326
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
326
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
Chronic Kidney Disease II: Clinical Manifestations
531
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
531
Chronic Kidney Disease IV: Nursing Management
307
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
307
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
228
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
228

